News APP

NewsApp (Free)

Read news as it happens
Download NewsApp

Available on  gplay

This article was first published 9 years ago
Rediff.com  » Business » Sun Pharma founder to invest $290 mn in turbine maker Suzlon

Sun Pharma founder to invest $290 mn in turbine maker Suzlon

By Aman Shah
February 14, 2015 15:03 IST
Get Rediff News in your Inbox:

Dilip SanghviThe founder of India's Sun Pharmaceutical Industries Inc, Dilip Sanghvi, has agreed to buy a 23 per cent stake in Indian wind turbine maker Suzlon Energy Ltd for about $290 million, the company said late on Friday.

Sanghvi, India's second-richest man, will pay 18 billion rupees through Dilip Sanghvi Family and Associates for 1 billion new shares in Suzlon, issued by way of a preferential allotment.

Sanghvi's investment firm and Suzlon will also form a wind farm joint venture for the development of 450 megawatt of wind farms, the statement said.

Loss-making Suzlon has been under pressure over the last few years due to a slowdown in global turbine sales and a growing debt pile. It was forced to restructure $1.8 billion of debt after defaulting on a $200 million convertible bond redemption in 2012.

The deal will provide Suzlon with much needed liquidity and the company said it would also use the cash to tap opportunities in India and growth markets like the United States, China, Brazil, South Africa, Turkey and Mexico.

Suzlon shares have risen 15 percent in the past week on media reports of Sanghvi's interest in investing in the company in a personal capacity. The company last week denied having received a proposal from Sanghvi.

Suzlon sold its German unit Senvion SE to buyout firm Centerbridge Partners last month for 1 billion euros in an all-cash deal, part of the company's plans to halve rupee debt by March 31.

Image: Sun Pharmaceutical Industries Ltd Director Dilip Shanghvi speaks during the Reuters India Summit in Mumbai. Photograph: Adeel Halim/Reuters

Get Rediff News in your Inbox:
Aman Shah in Mumbai
Source: REUTERS
© Copyright 2024 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
 

Moneywiz Live!